106 related articles for article (PubMed ID: 20213688)
21. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of allelic imbalances on chromosome 9p in stage I non-small cell lung carcinoma.
Tomizawa Y; Adachi J; Kohno T; Hamada K; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Yokota J
Clin Cancer Res; 1999 May; 5(5):1139-46. PubMed ID: 10353749
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage IIIA N2 non-small-cell lung cancer.
Takenaka K; Ishikawa S; Yanagihara K; Miyahara R; Hasegawa S; Otake Y; Morioka Y; Takahashi C; Noda M; Ito H; Wada H; Tanaka F
Ann Surg Oncol; 2005 Oct; 12(10):817-24. PubMed ID: 16132376
[TBL] [Abstract][Full Text] [Related]
24. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
[TBL] [Abstract][Full Text] [Related]
25. Surfactant protein A gene deletion and prognostics for patients with stage I non-small cell lung cancer.
Jiang F; Caraway NP; Nebiyou Bekele B; Zhang HZ; Khanna A; Wang H; Li R; Fernandez RL; Zaidi TM; Johnston DA; Katz RL
Clin Cancer Res; 2005 Aug; 11(15):5417-24. PubMed ID: 16061856
[TBL] [Abstract][Full Text] [Related]
26. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer.
Wang S; An T; Wang J; Zhao J; Wang Z; Zhuo M; Bai H; Yang L; Zhang Y; Wang X; Duan J; Wang Y; Guo Q; Wu M
Clin Cancer Res; 2010 Feb; 16(4):1324-30. PubMed ID: 20145159
[TBL] [Abstract][Full Text] [Related]
27. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
28. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors in resected pathologic (p-) stage IIIA-N2, non-small-cell lung cancer.
Tanaka F; Yanagihara K; Otake Y; Kawano Y; Miyahara R; Takenaka K; Katakura H; Ishikawa S; Ito H; Wada H
Ann Surg Oncol; 2004 Jun; 11(6):612-8. PubMed ID: 15150069
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer.
Sasaki H; Shimizu S; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
Lung Cancer; 2009 Jun; 64(3):295-300. PubMed ID: 19058870
[TBL] [Abstract][Full Text] [Related]
31. Tumor volume is a better prognostic factor than greatest tumor diameter in stage Ia non-small cell lung cancer.
Tsai CH; Lin CM; Hsieh CC; Hsu WH; Wang HW; Wang LS
Thorac Cardiovasc Surg; 2006 Dec; 54(8):537-43. PubMed ID: 17151969
[TBL] [Abstract][Full Text] [Related]
32. Clinical and Pathological Characteristics of
Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
[No Abstract] [Full Text] [Related]
33. Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC.
Saleh MM; Scheffler M; Merkelbach-Bruse S; Scheel AH; Ulmer B; Wolf J; Buettner R
J Thorac Oncol; 2022 Jan; 17(1):76-88. PubMed ID: 34601169
[TBL] [Abstract][Full Text] [Related]
34. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
[TBL] [Abstract][Full Text] [Related]
35. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Di Federico A; De Giglio A; Parisi C; Gelsomino F
Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
[TBL] [Abstract][Full Text] [Related]
36. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H
Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic significance of alterations in telomeric repeat length in patients with pathological stage I-II non-small cell lung cancer].
Hirashima T; Komiya T; Nitta T; Kobayashi M; Kawase I
Nihon Rinsho; 1998 May; 56(5):1264-71. PubMed ID: 9613135
[TBL] [Abstract][Full Text] [Related]
38. Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer.
Muscarella LA; Parrella P; D'Alessandro V; la Torre A; Barbano R; Fontana A; Tancredi A; Guarnieri V; Balsamo T; Coco M; Copetti M; Pellegrini F; De Bonis P; Bisceglia M; Scaramuzzi G; Maiello E; Valori VM; Merla G; Vendemiale G; Fazio VM
Epigenetics; 2011 Jun; 6(6):710-9. PubMed ID: 21610322
[TBL] [Abstract][Full Text] [Related]
39. Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial.
Rakaee M; Andersen S; Giannikou K; Paulsen EE; Kilvaer TK; Busund LR; Berg T; Richardsen E; Lombardi AP; Adib E; Pedersen MI; Tafavvoghi M; Wahl SGF; Petersen RH; Bondgaard AL; Yde CW; Baudet C; Licht P; Lund-Iversen M; Grønberg BH; Fjellbirkeland L; Helland Å; Pøhl M; Kwiatkowski DJ; Donnem T
Ann Oncol; 2023 Jul; 34(7):578-588. PubMed ID: 37100205
[TBL] [Abstract][Full Text] [Related]
40. PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.
Wang H; Shan Q; Guo J; Han X; Zhao C; Li H; Wang Z
Lung Cancer; 2021 Jan; 151():76-83. PubMed ID: 33246647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
